Skip to main content

Advertisement

SpringerLink
Log in

Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Background

High-dose methotrexate (HDMTX) (≥3 g/m2), the cornerstone of therapy for primary CNS lymphoma (PCNSL), is commonly dosed using a measured 24 h creatinine clearance (CrCl) every 2–4 weeks. Because these collections are cumbersome and at times unreliable, the use of a calculated CrCl was evaluated as a potential alternative.

Methods

A retrospective analysis was performed on data from all 287 treatment cycles from the 25 patients with PCNSL who participated in a multi-center phase II clinical trial of HDMTX conducted by the New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium.

Results

The 25 patients had a median age of 61 years (range 32–75). Seventeen (68%) were men. The patients received a median of 14 (range 2–21) HDMTX treatments. For 256 of 287 treatments (89%), data were available to compare the measured and calculated (using the Cockcroft–Gault equation) CrCl. The average measured CrCl was 93 ml/min (95% CI, 89–96 ml/min), and the average calculated CrCl was 107 ml/min (95% CI, 102–112 ml/min). The Pearson correlation coefficient (r) was 0.49 (P < 0.0001) between the measured and calculated CrCl. The average MTX dose determined using measured CrCl was 14.1 g (95% CI, 13.6–14.5 g), and the average MTX dose determined using calculated CrCl was 14.7 g (95% CI, 14.2–15.1 g). MTX doses based on measured and calculated CrCl were significantly correlated (r = 0.72, P < 0.0001). Of the 256 HDMTX treatments evaluated, 158 (62%) had reliable 48 h serum MTX levels documented. Forty-seven levels (30%) were within target range (0.3–1 μmol/l), 99 levels (62%) were below target range (<0.3 μmol/l), 12 levels (8%) were in the range associated with mild toxicity range (>1–3 μmol/l), and no levels were in the range associated with severe toxicity (>3 μmol/l). Of these 158 treatments, the use of a calculated rather than measured CrCl would have yielded an identical MTX dose for 48 treatments (30%), a higher MTX dose for 62 treatments (40%), and a lower MTX dose for 48 treatments (30%). This distribution was not significantly different among the subsets of below target, within target range, and above target MTX levels (P = 0.87).

Conclusions

In this cohort of patients with PCNSL, there is significant correlation between the calculated and measured CrCl. MTX doses determined using calculated and measured CrCl are not significantly different. For these patients, there is no clear association between the method of determining CrCl and serum MTX levels. As a result, calculated CrCl is a reasonable alternative to measured CrCl in this patient population and would avoid the inconvenience and potential inaccuracies associated with measured CrCl.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

PCNSL:

Primary central nervous system lymphoma

HDMTX:

High-dose methotrexate

MTX:

Methotrexate

NABTT:

New Approaches to Brain Tumor Therapy

CrCl:

Creatinine clearance

Cr:

Creatinine

ABW:

Actual body weight

BSA:

Body surface area

GFR:

Glomerular filtration rate

99mTc-DTPA:

Technetium-99m diethylenetriamine penta-acetic acid

References

  1. Batchelor T, Carson K, O’Neill A, Grossman SA, Alavi J, New P, Hochberg F, Priet R (2003) Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 21:1044–1049

    Article  PubMed  CAS  Google Scholar 

  2. Bleyer WA (1977) Methotrexate: clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev 4:87–101

    Article  PubMed  CAS  Google Scholar 

  3. Chambers JT, Chambers SK, Schwartz PE (1990) Correlation between measured creatinine clearance and calculated creatinine clearance in ovarian cancer patients. Gyn Oncol 36:66–68

    Article  CAS  Google Scholar 

  4. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41

    PubMed  CAS  Google Scholar 

  5. Davila E, Gardner LB (1987) Clinical value of the creatinine clearance before the administration of chemotherapy with cisplatin. Cancer 60:161–164

    Article  PubMed  CAS  Google Scholar 

  6. Evans WE, Crom WR, Stewart CF, Bowman WP, Chen CH, Abromowitch M, Simone JV (1984) Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia. Lancet 1:359–362

    Article  PubMed  CAS  Google Scholar 

  7. Evans WE, Pratt CB, Taylor RH, Barker LF, Crom WR (1979) Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Cancer Chemother Pharmacol 3:161–166

    Article  PubMed  CAS  Google Scholar 

  8. Ferreri AJ, Guerra E, Regazzi M, Pasini F, Ambrosetti A, Pivnik A, Gubkin A, Calderoni A, Spina M, Brandes A, Ferrarese F, Rognone A, Govi S, Dell’Oro S, Locatelli M, Villa E, Reni M (2004) Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 90:353–358

    Article  PubMed  CAS  Google Scholar 

  9. Guha-Thakurta N, Damek D, Pollack C, Hochberg FH (1999) Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neuro-Oncol 43:259–268

    Article  CAS  Google Scholar 

  10. Haim N, Oman SD, Galai N, Burde B, Nathan S, Catane R (1993) Estimation of creatinine clearance without 24-hour urine collection: a useful guide during cisplatin therapy. Acta Oncol 32:409–412

    PubMed  CAS  Google Scholar 

  11. Jacobson P, West N, Hutchinson RJ (1997) Predictive ability of creatinine clearance estimate models in pediatric bone marrow transplant patients. Bone Marrow Trans 19:481–485

    Article  CAS  Google Scholar 

  12. Jahnke K, Korfel A, Martus P, Weller M, Herrlinger U, Schmittel A, Fischer L, Thiel E (2005) On the behalf of the German Primary Central Nervous System Lymphoma Study Group (G-PCNSL-SG) High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 16:445–449

    Article  PubMed  CAS  Google Scholar 

  13. Joannon P, Oviedo I, Campbell M, Tordecilla J (2004) High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance. Pediatr Blood Cancer 43:17–22

    Article  PubMed  Google Scholar 

  14. McDermott DF, Galindo A, Sherman RL, Jaffe EA, Coleman M, Pasmantier MW (1987) Inadequacy of predicted creatinine clearance as guide to chemotherapy. Cancer Treat Rep 71:1067–1069

    PubMed  CAS  Google Scholar 

  15. Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, Tolcher AW, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz JE, Simms L, Chaudhary AK, Johnson RD, Rowinsky EK, Takimoto CH (2006) Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 24:552–562

    Article  PubMed  CAS  Google Scholar 

  16. Morgan DB, Dillon S, Payne RB (1978) The assessment of glomerular function: creatinine clearance or plasma creatinine. Postgrad Med J 54:302–310

    Article  PubMed  CAS  Google Scholar 

  17. Mosteller RD (1987) Simplified calculation of body-surface area. New Engl J Med 317:1098

    PubMed  CAS  Google Scholar 

  18. National Comprehensive Cancer Center Guildelines 4/18/2006-last update, NCCN practice guidelines in oncology: non-immunosuppressed primary CNS lymphoma

  19. Nirenberg A, Mosende C, Mehta BM, Gisolfi AL, Rosen G (1977) High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity. Cancer Treat Rep 61:779–783

    PubMed  CAS  Google Scholar 

  20. Payne RB (1986) Creatinine clearance: a redundant clinical investigation. Ann Clin Biochem 23(Pt 3):243–250

    PubMed  Google Scholar 

  21. Relling MV, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, Evans WE (1994) Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 12:1667–1672

    PubMed  CAS  Google Scholar 

  22. Robinson BA, Frampton CM, Colls BM, Atkinson CH, Fitzharris BM (1990) Comparison of methods of assessment of renal function in patients with cancer treated with cisplatin, carboplatin or methotrexate. Aust N Z J Med 20:657–662

    CAS  Google Scholar 

  23. Rosano TG, Brown HH (1982) Analytical and biological variability of serum creatinine and creatinine clearance: implications for clinical interpretation. Clin Chem 28:2330–2331

    PubMed  CAS  Google Scholar 

  24. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA (1977) Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. New Engl J Med 297:630–634

    Article  PubMed  CAS  Google Scholar 

  25. Tsubaki T, Goodin S, Leader WG, Chandler MH (1993) Estimation of creatinine clearance in patients with gynecologic cancer. Clin Pharm 12:685–690

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium, 1550 Orleans Street, Cancer Research Building II, Suite 1M16, Baltimore, MD, 21231, USA

    David E. Gerber, Stuart A. Grossman, Tracy Batchelor & Xiaobu Ye

Authors
  1. David E. Gerber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stuart A. Grossman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tracy Batchelor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaobu Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stuart A. Grossman.

Additional information

Presented in abstract format at the Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2–6, 2006.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gerber, D.E., Grossman, S.A., Batchelor, T. et al. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma. Cancer Chemother Pharmacol 59, 817–823 (2007). https://doi.org/10.1007/s00280-006-0339-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-006-0339-x

Keywords

Search

Navigation